Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of Caelyx in combination with carboplatin in patients with ovarian cancer that recurs within six to twelve mo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED